TSX:NDN
PRICE: $
CHANGE:
VOLUME:32,988
NYSE:NDZ
PRICE: $
CHANGE:
VOLUME:141,266
(Jul 31, 2011)
Market cap of
C$648M
(Jul 31, 2011)
·
More Stock Info
Name Change
The Company officially changed its name to Nordion Inc. on November 1, 2010. Prior to November the Company's name was MDS Inc.
Why Invest? The Nordion Advantage
To fulfill our commitment to shareholders, we are focused on investing in growth, managing our market positions, and executing our strategic plans with operational and financial discipline in order to drive strong cash flow and growth both in the present and into the future.
Read our investor presentation below, and refer to the options on to the right to discover four great reasons to invest in Nordion.
Significant Growth Opportunity
- Building leadership in the emerging field of interventional oncology (IO)
- TheraSphere achieved 47% growth in fiscal 2011 to revenues of $42.6M
- Solid long-term growth expected from TheraSphere
- Expanding leadership position in Sterilization Technologies to emerging markets such as China
- Investments in R&D for TheraSphere clinical trial programs and new product offerings such as the GammaFIT irradiator
Competitive Edge
- Extensive domain expertise with more than 40 years of commercial radioisotopes experience
- Long-term and exclusive relationships with strategic suppliers
- High barriers to entry - significant capital investment and several years of preparation required by new entrants
in our markets
- Manage over 500 customer accounts worldwide, with long-term relationships at the executive level
Strong Management & Operating Team
- Record of executing strategic objectives
- Successful management of strategic repositioning
- CEO 8+ year Nordion leader with prior global CEO experience
- Seasoned executives with broad industry experience in Operations, Quality, Regulatory, S&M, R&D and Clinical Affairs
- Employs more than 500 highly skilled people
Strong Margins & Cash Flow Streams
- Solid cash flows from each business segment
- Strong balance sheet, with additional financial flexibility through $75M credit facility
- Core products with high margin contributions
- Disciplined capital allocation - $71.6M returned to shareholders by way of share buy backs and dividends in fiscal 2011
